LLY - ELI LILLY & Co
917.5
-0.550 -0.060%
Share volume: 2,361,168
Last Updated: 03-19-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.16%
PREVIOUS CLOSE
CHG
CHG%
$918.05
-0.55
0.00%
Fundamental analysis
59%
Profitability
75%
Dept financing
22%
Liquidity
37%
Performance
57%
Performance
5 Days
-7.24%
1 Month
-9.12%
3 Months
-14.77%
6 Months
21.53%
1 Year
8.89%
2 Year
18.71%
Key data
Stock price
$917.50
DAY RANGE
$910.86 - $924.53
52 WEEK RANGE
$623.78 - $1,133.95
52 WEEK CHANGE
$9.54
DIVIDEND
$1.73
EX-DIVIDEND DATE
02-13-2026
NEXT EARNINGS DATE
08-07-2025
Company detail
CEO: David A. Ricks
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax
Recent news